NZ555176A - Methods for administering DPD inhibitors in combination with 5-FU and 5-FU prodrugs - Google Patents
Methods for administering DPD inhibitors in combination with 5-FU and 5-FU prodrugsInfo
- Publication number
- NZ555176A NZ555176A NZ555176A NZ55517605A NZ555176A NZ 555176 A NZ555176 A NZ 555176A NZ 555176 A NZ555176 A NZ 555176A NZ 55517605 A NZ55517605 A NZ 55517605A NZ 555176 A NZ555176 A NZ 555176A
- Authority
- NZ
- New Zealand
- Prior art keywords
- eniluracil
- prodrug
- dose
- medicament
- formulated
- Prior art date
Links
- 229960002949 fluorouracil Drugs 0.000 title claims abstract description 274
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 title claims abstract description 262
- 239000003112 inhibitor Substances 0.000 title claims abstract description 121
- 229940002612 prodrug Drugs 0.000 title claims description 23
- 239000000651 prodrug Substances 0.000 title claims description 23
- 238000000034 method Methods 0.000 title description 33
- 102100022334 Dihydropyrimidine dehydrogenase [NADP(+)] Human genes 0.000 claims abstract description 154
- UEJQGOKMPMUMTO-UHFFFAOYSA-N C(C#C)OC1=NC=C(C(=N1)OCC#C)F Chemical compound C(C#C)OC1=NC=C(C(=N1)OCC#C)F UEJQGOKMPMUMTO-UHFFFAOYSA-N 0.000 claims abstract description 87
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 50
- 239000003814 drug Substances 0.000 claims abstract description 44
- 201000011510 cancer Diseases 0.000 claims abstract description 39
- 238000002360 preparation method Methods 0.000 claims abstract description 15
- JOZGNYDSEBIJDH-UHFFFAOYSA-N eniluracil Chemical group O=C1NC=C(C#C)C(=O)N1 JOZGNYDSEBIJDH-UHFFFAOYSA-N 0.000 claims description 185
- 229950010213 eniluracil Drugs 0.000 claims description 183
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 18
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 17
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Natural products O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 17
- 229960004117 capecitabine Drugs 0.000 claims description 17
- -1 5'-deoxy-4' Chemical compound 0.000 claims description 14
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 125000005843 halogen group Chemical group 0.000 claims description 9
- 229940035893 uracil Drugs 0.000 claims description 9
- 230000002441 reversible effect Effects 0.000 claims description 7
- BLXGZIDBSXVMLU-OWOJBTEDSA-N 5-[(e)-2-bromoethenyl]-1h-pyrimidine-2,4-dione Chemical compound Br\C=C\C1=CNC(=O)NC1=O BLXGZIDBSXVMLU-OWOJBTEDSA-N 0.000 claims description 6
- FHIDNBAQOFJWCA-UAKXSSHOSA-N 5-fluorouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 FHIDNBAQOFJWCA-UAKXSSHOSA-N 0.000 claims description 6
- UJBCLAXPPIDQEE-UHFFFAOYSA-N 5-prop-1-ynyl-1h-pyrimidine-2,4-dione Chemical compound CC#CC1=CNC(=O)NC1=O UJBCLAXPPIDQEE-UHFFFAOYSA-N 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 6
- 230000002427 irreversible effect Effects 0.000 claims description 6
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 4
- HAUXRJCZDHHADG-UHFFFAOYSA-N 2,4-dioxo-1h-pyrimidine-5-carbonitrile Chemical compound O=C1NC=C(C#N)C(=O)N1 HAUXRJCZDHHADG-UHFFFAOYSA-N 0.000 claims description 4
- XFPGPBKTWIFNAA-UHFFFAOYSA-N 5-(2-bromo-1-chloroethenyl)-1h-pyrimidine-2,4-dione Chemical compound BrC=C(Cl)C1=CNC(=O)NC1=O XFPGPBKTWIFNAA-UHFFFAOYSA-N 0.000 claims description 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- IDYKCXHJJGMAEV-RRKCRQDMSA-N 4-amino-5-fluoro-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound C1=C(F)C(N)=NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)C1 IDYKCXHJJGMAEV-RRKCRQDMSA-N 0.000 claims description 3
- CYMBDTMRFAUHRM-UHFFFAOYSA-N 5-(1-chloroethenyl)-1h-pyrimidine-2,4-dione Chemical compound ClC(=C)C1=CNC(=O)NC1=O CYMBDTMRFAUHRM-UHFFFAOYSA-N 0.000 claims description 3
- LKTQRCSUYNIRSM-UHFFFAOYSA-N 5-(2-bromoethynyl)-1h-pyrimidine-2,4-dione Chemical compound BrC#CC1=CNC(=O)NC1=O LKTQRCSUYNIRSM-UHFFFAOYSA-N 0.000 claims description 3
- FBOIBTWYSVRYTJ-VBLCRABPSA-N 5-[(3S,4S,5S)-6-fluoro-3,4,5-trihydroxyoxan-2-yl]-1H-pyrimidine-2,4-dione Chemical compound FC1[C@H]([C@H]([C@@H](C(O1)C=1C(NC(NC=1)=O)=O)O)O)O FBOIBTWYSVRYTJ-VBLCRABPSA-N 0.000 claims description 3
- LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 claims description 3
- ZRYZBEQILKESAW-UHFFFAOYSA-N 5-ethenyl-1h-pyrimidine-2,4-dione Chemical compound C=CC1=CNC(=O)NC1=O ZRYZBEQILKESAW-UHFFFAOYSA-N 0.000 claims description 3
- STRZQWQNZQMHQR-UAKXSSHOSA-N 5-fluorocytidine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 STRZQWQNZQMHQR-UAKXSSHOSA-N 0.000 claims description 3
- KSNXJLQDQOIRIP-UHFFFAOYSA-N 5-iodouracil Chemical compound IC1=CNC(=O)NC1=O KSNXJLQDQOIRIP-UHFFFAOYSA-N 0.000 claims description 3
- KFRZFMXZIDRZJI-UHFFFAOYSA-N 5-phenylselanyl-1,3-diazinane-2,4,6-trione Chemical compound O=C1NC(=O)NC(=O)C1[Se]C1=CC=CC=C1 KFRZFMXZIDRZJI-UHFFFAOYSA-N 0.000 claims description 3
- ZEGGHGSNGZPEHQ-UHFFFAOYSA-N 5-phenylselanyl-1h-pyrimidine-2,4-dione Chemical group O=C1NC(=O)NC=C1[Se]C1=CC=CC=C1 ZEGGHGSNGZPEHQ-UHFFFAOYSA-N 0.000 claims description 3
- KRPWRQUISWCMBL-UHFFFAOYSA-N 5-phenylsulfanyl-1,3-diazinane-2,4,6-trione Chemical compound O=C1NC(=O)NC(=O)C1SC1=CC=CC=C1 KRPWRQUISWCMBL-UHFFFAOYSA-N 0.000 claims description 3
- MFORXTHLVUSZNY-UHFFFAOYSA-N 5-phenylsulfanyl-1h-pyrimidine-2,4-dione Chemical compound O=C1NC(=O)NC=C1SC1=CC=CC=C1 MFORXTHLVUSZNY-UHFFFAOYSA-N 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 claims description 3
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 claims description 3
- 150000003014 phosphoric acid esters Chemical class 0.000 claims description 3
- VXFDYPMVKAHYHJ-WLHGVMLRSA-N 5-[(e)-2-bromoethenyl]-1h-pyrimidine-2,4-dione;5-hex-1-ynyl-1h-pyrimidine-2,4-dione Chemical compound Br\C=C\C1=CNC(=O)NC1=O.CCCCC#CC1=CNC(=O)NC1=O VXFDYPMVKAHYHJ-WLHGVMLRSA-N 0.000 claims 1
- WFWLQNSHRPWKFK-UHFFFAOYSA-N Tegafur Chemical compound O=C1NC(=O)C(F)=CN1C1OCCC1 WFWLQNSHRPWKFK-UHFFFAOYSA-N 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 33
- 238000009472 formulation Methods 0.000 description 31
- 230000008030 elimination Effects 0.000 description 22
- 238000003379 elimination reaction Methods 0.000 description 22
- 230000000259 anti-tumor effect Effects 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 238000011282 treatment Methods 0.000 description 12
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 11
- 230000002503 metabolic effect Effects 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 6
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 5
- 102000006405 Uridine phosphorylase Human genes 0.000 description 5
- 108010019092 Uridine phosphorylase Proteins 0.000 description 5
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 5
- 235000008191 folinic acid Nutrition 0.000 description 5
- 239000011672 folinic acid Substances 0.000 description 5
- 230000002779 inactivation Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 229960001691 leucovorin Drugs 0.000 description 5
- 239000002547 new drug Substances 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 5
- 229940045145 uridine Drugs 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 102000029785 Orotate phosphoribosyltransferase Human genes 0.000 description 4
- 108010055012 Orotidine-5'-phosphate decarboxylase Proteins 0.000 description 4
- 101710132082 Pyrimidine/purine nucleoside phosphorylase Proteins 0.000 description 4
- 102000013537 Thymidine Phosphorylase Human genes 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000000937 inactivator Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000004005 microsphere Substances 0.000 description 4
- 150000003833 nucleoside derivatives Chemical class 0.000 description 4
- 238000011533 pre-incubation Methods 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 230000003442 weekly effect Effects 0.000 description 4
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000011260 co-administration Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- BFHKYHMCIAMQIN-UHFFFAOYSA-N 2-hydroxy-6-oxo-1h-pyridine-3-carbonitrile Chemical compound OC=1NC(=O)C=CC=1C#N BFHKYHMCIAMQIN-UHFFFAOYSA-N 0.000 description 2
- 241000220479 Acacia Species 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000002375 Hand-Foot Syndrome Diseases 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- GCQYYIHYQMVWLT-HQNLTJAPSA-N Sorivudine Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(\C=C\Br)=C1 GCQYYIHYQMVWLT-HQNLTJAPSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000001195 anabolic effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 2
- 229960001674 tegafur Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 230000036964 tight binding Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- SSKDHFQACCNHRE-UHFFFAOYSA-N 1,3,5-trifluoropyrimidine-2,4-dione Chemical compound FC1=CN(F)C(=O)N(F)C1=O SSKDHFQACCNHRE-UHFFFAOYSA-N 0.000 description 1
- MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 description 1
- BLXGZIDBSXVMLU-UHFFFAOYSA-N 5-(2-bromoethenyl)-1h-pyrimidine-2,4-dione Chemical compound BrC=CC1=CNC(=O)NC1=O BLXGZIDBSXVMLU-UHFFFAOYSA-N 0.000 description 1
- LMNPKIOZMGYQIU-UHFFFAOYSA-N 5-(trifluoromethyl)-1h-pyrimidine-2,4-dione Chemical compound FC(F)(F)C1=CNC(=O)NC1=O LMNPKIOZMGYQIU-UHFFFAOYSA-N 0.000 description 1
- POYNHVFBISCPAG-DJLDLDEBSA-N 5-ethynyl-1-[(2r,4s,5r)-4-fluoro-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound C1[C@H](F)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C#C)=C1 POYNHVFBISCPAG-DJLDLDEBSA-N 0.000 description 1
- LTBQNWHGFBPRNE-UHFFFAOYSA-N 5-ethynyl-1h-pyrimidin-2-one Chemical compound O=C1N=CC(C#C)=CN1 LTBQNWHGFBPRNE-UHFFFAOYSA-N 0.000 description 1
- HFEKDTCAMMOLQP-RRKCRQDMSA-N 5-fluorodeoxyuridine monophosphate Chemical compound O1[C@H](COP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C(F)=C1 HFEKDTCAMMOLQP-RRKCRQDMSA-N 0.000 description 1
- TUFMBCUUDJKPJB-UHFFFAOYSA-N 5-hex-1-ynyl-1h-pyrimidine-2,4-dione Chemical compound CCCCC#CC1=CNC(=O)NC1=O TUFMBCUUDJKPJB-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- FGIIHDQJUQKPND-UHFFFAOYSA-N BrC=1C(NC(NC1C#C)=O)=O Chemical compound BrC=1C(NC(NC1C#C)=O)=O FGIIHDQJUQKPND-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102100036360 Cadherin-3 Human genes 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010066455 Dihydrouracil Dehydrogenase (NADP) Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 241000287227 Fringillidae Species 0.000 description 1
- 101000714553 Homo sapiens Cadherin-3 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- HKUJAJKSNVIDLX-RRKCRQDMSA-N [(2R,3S,5R)-5-(5-fluoro-2,4-dioxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C(F)=C1 HKUJAJKSNVIDLX-RRKCRQDMSA-N 0.000 description 1
- YQOCUTDPKPPQGA-RRKCRQDMSA-N [[(2r,3s,5r)-5-(5-fluoro-2,4-dioxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C(F)=C1 YQOCUTDPKPPQGA-RRKCRQDMSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 150000008209 arabinosides Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- KVUAALJSMIVURS-QNTKWALQSA-L calcium;(2s)-2-[[4-[[(6s)-2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]pentanedioate Chemical compound [Ca+2].C([C@@H]1N(C=O)C=2C(=O)N=C(NC=2NC1)N)NC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-QNTKWALQSA-L 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000012792 core layer Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- MXHRCPNRJAMMIM-UHFFFAOYSA-N desoxyuridine Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 231100001264 fatal toxicity Toxicity 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 150000005699 fluoropyrimidines Chemical class 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- WLQBZMZTRNPUDL-BBVRLYRLSA-N fudp Chemical compound C1[C@H](F)[C@@H](CO[P@](O)(=O)OP(O)(=O)O)O[C@@H]1N1C(=O)NC(=O)C=C1 WLQBZMZTRNPUDL-BBVRLYRLSA-N 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- ABQZFXNDCVIZHH-CGEWXTDFSA-N pentyl (2s,3r,4s,5r)-2-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxy-5-(hydroxymethyl)oxolane-2-carboxylate Chemical compound C1=CC(N)=NC(=O)N1[C@]1(C(=O)OCCCCC)O[C@H](CO)[C@@H](O)[C@H]1O ABQZFXNDCVIZHH-CGEWXTDFSA-N 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229950009279 sorivudine Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 229940053867 xeloda Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63303404P | 2004-12-03 | 2004-12-03 | |
| PCT/US2005/043706 WO2006060697A1 (en) | 2004-12-03 | 2005-12-05 | Methods for administering dpd inhibitors in combination with 5-fu and 5-fu prodrugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ555176A true NZ555176A (en) | 2010-03-26 |
Family
ID=36087538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ555176A NZ555176A (en) | 2004-12-03 | 2005-12-05 | Methods for administering DPD inhibitors in combination with 5-FU and 5-FU prodrugs |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8318756B2 (enExample) |
| EP (1) | EP1827443A1 (enExample) |
| JP (2) | JP2008521930A (enExample) |
| KR (1) | KR20070098798A (enExample) |
| CN (2) | CN101068549A (enExample) |
| AU (1) | AU2005311730B2 (enExample) |
| CA (1) | CA2587514A1 (enExample) |
| MX (1) | MX2007006646A (enExample) |
| NZ (1) | NZ555176A (enExample) |
| WO (1) | WO2006060697A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101068549A (zh) * | 2004-12-03 | 2007-11-07 | 阿迪赫里克斯技术公司 | 与5－fu和5－fu前药组合施用dpd抑制剂的方法 |
| US20090196833A1 (en) * | 2008-02-06 | 2009-08-06 | Adherex Technologies Inc. | Compositions comprising topical dpd inhibitors and methods of using same in the treatment of hand-foot syndrome |
| WO2009118712A2 (en) * | 2008-03-27 | 2009-10-01 | Ecole Polytechnique Federale De Lausanne (Epfl) | Novel dihydroxypyrrolidine derivatives as anti-cancer agents |
| BR112012000873A2 (pt) * | 2009-07-17 | 2019-11-05 | Myriad Genetics Inc | método de dosar 5-fluorouracil em uma amostra de um paciente tratado com f-fu ou um pró-fármaco deste, método de tratar um paciente com 5-fluorouracil ou um pró-fármaco deste, método de processamento de uma amostra de sangue de um paciente tratado com um regime compreendendo 5-fluorouracil ou um pró-fármaco deste para um teste de 5-fluorouracil, método de processamento de uma amostra de sangue de um paciente tratado com um regime compreendendo 5-fluorouracil ou um pró-fármaco deste, composição, kit, kit de teste, conjunto de seringa de transferência |
| BR112012008951A2 (pt) | 2009-10-14 | 2019-09-24 | Adherex Tech Inc | tratamento de neurotoxidez associada com combinações de 5-fu ou seus profármacos e inibidores de dpd |
| WO2014089004A1 (en) * | 2012-12-04 | 2014-06-12 | Adherex Technologies, Inc. | Methods for treating 5-fluorouracil prodrug non-responsive cancer patients |
| CN106692173A (zh) * | 2015-11-18 | 2017-05-24 | 北京诺普德医药科技有限公司 | 一种抗肿瘤复方组合物及其应用 |
| CN106619689B (zh) | 2016-12-30 | 2018-05-01 | 陈晓华 | 一种用于治疗癌症的药物组合物、试剂盒及其应用 |
| WO2020125550A1 (zh) * | 2018-12-19 | 2020-06-25 | 广州君赫生物科技有限公司 | 化合物在治疗与saicar累积相关的疾病的用途 |
| CN109655606A (zh) * | 2019-01-11 | 2019-04-19 | 华东师范大学 | 一种利用3d类器官评价药物肠毒性的检测方法 |
| WO2023283921A1 (zh) * | 2021-07-16 | 2023-01-19 | 北京深蓝泰医药科技有限公司 | Dpd抑制剂及其药物组合物和用途 |
| US20240180910A1 (en) * | 2022-12-06 | 2024-06-06 | Elion Oncology, Inc. | Method for treating cancer with a chemotherapeutic modifier |
| US20250017931A1 (en) * | 2023-07-13 | 2025-01-16 | Processa Pharmaceuticals, Inc., | Methods of personalizing cancer treatment |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8629892D0 (en) | 1986-12-15 | 1987-01-28 | Wellcome Found | Antiviral compounds |
| US5157114A (en) | 1988-08-19 | 1992-10-20 | Burroughs Wellcome Co. | 2',3'-dideoxy-3'-fluoro-5-ethyngluridine |
| EP0539442B1 (en) | 1990-07-19 | 1998-01-07 | The Wellcome Foundation Limited | Enzyme inactivators |
| GB9020930D0 (en) | 1990-09-26 | 1990-11-07 | Wellcome Found | Pharmaceutical combinations |
| IT1255522B (it) * | 1992-09-24 | 1995-11-09 | Ubaldo Conte | Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita' |
| US5476855A (en) | 1993-11-02 | 1995-12-19 | Mahmoud H. el Kouni | Enzyme inhibitors, their synthesis and methods for use |
| NZ330360A (en) | 1997-06-02 | 1999-03-29 | Hoffmann La Roche | 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents |
| US6716452B1 (en) * | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| US20040028687A1 (en) | 2002-01-15 | 2004-02-12 | Waelti Ernst Rudolf | Methods and compositions for the targeted delivery of therapeutic substances to specific cells and tissues |
| CN101068549A (zh) * | 2004-12-03 | 2007-11-07 | 阿迪赫里克斯技术公司 | 与5－fu和5－fu前药组合施用dpd抑制剂的方法 |
-
2005
- 2005-12-05 CN CNA2005800414059A patent/CN101068549A/zh active Pending
- 2005-12-05 KR KR1020077013028A patent/KR20070098798A/ko not_active Ceased
- 2005-12-05 MX MX2007006646A patent/MX2007006646A/es active IP Right Grant
- 2005-12-05 CN CN2011104284155A patent/CN102441170A/zh active Pending
- 2005-12-05 EP EP05852819A patent/EP1827443A1/en not_active Withdrawn
- 2005-12-05 AU AU2005311730A patent/AU2005311730B2/en not_active Ceased
- 2005-12-05 US US11/294,643 patent/US8318756B2/en active Active
- 2005-12-05 JP JP2007544558A patent/JP2008521930A/ja active Pending
- 2005-12-05 WO PCT/US2005/043706 patent/WO2006060697A1/en not_active Ceased
- 2005-12-05 CA CA002587514A patent/CA2587514A1/en not_active Abandoned
- 2005-12-05 NZ NZ555176A patent/NZ555176A/en not_active IP Right Cessation
-
2012
- 2012-08-27 JP JP2012186899A patent/JP2012229273A/ja active Pending
- 2012-11-27 US US13/686,240 patent/US20130184232A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005311730A1 (en) | 2006-06-08 |
| US20130184232A1 (en) | 2013-07-18 |
| JP2008521930A (ja) | 2008-06-26 |
| KR20070098798A (ko) | 2007-10-05 |
| WO2006060697A1 (en) | 2006-06-08 |
| JP2012229273A (ja) | 2012-11-22 |
| EP1827443A1 (en) | 2007-09-05 |
| CA2587514A1 (en) | 2006-06-08 |
| MX2007006646A (es) | 2007-11-16 |
| CN101068549A (zh) | 2007-11-07 |
| US20060148753A1 (en) | 2006-07-06 |
| WO2006060697A9 (en) | 2006-09-21 |
| US8318756B2 (en) | 2012-11-27 |
| AU2005311730B2 (en) | 2011-11-17 |
| CN102441170A (zh) | 2012-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20130184232A1 (en) | Methods for administering dpd inhibitors in combination with 5-fu and 5-fu prodrugs | |
| Tonkinson et al. | Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma | |
| Álvarez et al. | 5-Fluorouracil derivatives: a patent review | |
| EP1849470B2 (en) | Anticancer drug containing alpha, alpha, alpha-trifluorothymidine and thymidine phosphorylase inhibitor | |
| CN114727996A (zh) | 用于治疗白血病或骨髓增生异常综合征的与维奈托克、吉瑞替尼、米哚妥林或其他化合物组合的阿扎胞苷 | |
| US7799783B2 (en) | Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor | |
| Soo et al. | A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer | |
| CA2542235A1 (en) | Methods, compositions, and kits for organ protection during systemic anticancer therapy | |
| AU2010306698B2 (en) | Treating neurotoxicity associated with combinations of 5 - FU or its prodrugs and DPD inhibitors | |
| AU2012200856B2 (en) | Methods for administering DPD inhibitors in combination with 5-FU and 5-FU prodrugs | |
| JP6845332B2 (ja) | がん治療用医薬組成物及びその使用 | |
| US20080255168A1 (en) | Methods for administering dpd inhibitors in combination with 5-fu and 5-fu prodrugs | |
| HK1110531A (en) | Methods for administering dpd inhibitors in combination with 5-fu and 5-fu prodrugs | |
| Lewis et al. | Oral fluoropyrimidines in cancer treatment | |
| WO2014089004A1 (en) | Methods for treating 5-fluorouracil prodrug non-responsive cancer patients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| LAPS | Patent lapsed |